MedTrace Logo

Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)

NCT03099031 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 420

Last updated 2019-12-16

No results posted yet for this study

Summary

The purpose of this study is to validate the Ottawa score (risk of thromboembolic recurrences) in cancer patients with thromboembolic disease treated with tinzaparin (Innohep®)

Conditions

  • Venous Thromboembolism

Interventions

DRUG

Tinzaparin

Subcutaneous injection of 175 IU/kg once daily for 6 months

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • G Meyer, Professor · Service de pneumologie et de soins intensifs, Hôpital Européen Georges Pompidou, Paris

  • F Scotte, Dr · Unité fonctionnelle de soins oncologiques de support, Hôpital Européen Georges Pompidou, Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2017-05-15
Completion
2017-05-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03099031 on ClinicalTrials.gov